Live Chat ×
Skip to main content

MDS Progression to AML: What Patients Need to Know

During this program, recorded on September 29, 2015, Dr. Warlick focuses on helping you understand new and emerging diagnostic procedures and prognostic models that help physicians determine a patient’s risk for progression from MDS to AML.

Treatment options if there is disease progression to AML are also discussed. There is an ever present risk of MDS progressing into acute myeloid leukemia (AML), which does not respond well to chemotherapy. AML is a bone marrow malignancy where the marrow is replaced by a population of extremely immature or primitive "blast" or stem cells. Therefore, there is a severe shortage of normal cells.